Clinical Evaluation of a BALIMONT Bifidobacterium–Lactobacillus plantarum Synbiotic Complex for Gut Microbiota and Bowel Function in Adults

Anas Ziraoui; Lorenzo Caruso; Zion Walker

doi:10.54691/yr1bd653

Authors

Anas Ziraoui
Lorenzo Caruso
Zion Walker

DOI:

https://doi.org/10.54691/yr1bd653

Keywords:

BALIMONT; Bifidobacterium longum; Bifidobacterium adolescentis; Lactobacillus plantarum; synbiotic; bowel function; constipation; gut microbiota; irritable bowel syndrome.

Abstract

Background: We positioned a BALIMONT synbiotic composition built around freeze-dried Bifidobacterium longum, Bifidobacterium adolescentis, Lactobacillus plantarum, fructooligosaccharides, and stachyose for adult intestinal-health use. To place this formulation within a credible clinical framework, we integrated our retained formulation and preclinical observations with publicly available randomized trials and meta-analyses. Methods: We searched the adult PubMed literature through March 2026 for randomized controlled trials, synbiotic/probiotic studies, and meta-analyses related to constipation, bowel function, gut microbiota, irritable bowel syndrome, Bifidobacterium, Lactobacillus plantarum, and prebiotic oligosaccharides. Results: Public clinical evidence indicates that probiotics can shorten whole-gut transit time and improve stool frequency and stool consistency in functional constipation, with stronger pooled signals for multi-species formulations. A randomized trial containing Bifidobacterium longum showed earlier normalization of stool frequency and consistency, while synbiotic trials demonstrated gains in evacuation frequency and bowel regularity. In older adults with functional constipation, BL-99 plus fructooligosaccharides improved weekly spontaneous bowel movements and whole-gut transit time relative to placebo. For IBS-like symptoms, L. plantarum 299v and contemporary multistrain synbiotics demonstrated benefit in some adult populations, although the overall meta-analytic certainty remains low and strain heterogeneity is substantial. Conclusions: The present formulation is best supported as a synbiotic intervention for bowel regularity, microbiota modulation, and symptom support. The most persuasive translational bridge comes from adult constipation and mixed functional gastrointestinal evidence, combined with our formulation architecture and preclinical observations.

Downloads

Download data is not yet available.

References

[1] Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66.

[2] Gibson GR, Hutkins R, Sanders ME, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491-502. doi:10.1038/nrgastro.2017.75.

[3] Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17(11):687-701. doi:10.1038/s41575-020-0344-2.

[4] Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(4):1075-1084. doi:10.3945/ajcn.114.089151.

[5] Zhang C, Jiang J, Tian F, et al. Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults. Clin Nutr. 2020; 39(10): 2960-2969. doi:10.1016/j.clnu.2020.01.005.

[6] Martoni CJ, Evans M, Chow CE, Chan LS, Leyer G. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial. J Dig Dis. 2019;20(9):435-446. doi:10.1111/1751-2980.12797.

[7] Waitzberg DL, Logullo L, Bittencourt A, et al. Effect of synbiotic in constipated adult women - a randomized, double-blind, placebo-controlled study of clinical response. Clin Nutr. 2013; 32(1): 27-33. doi:10.1016/j.clnu.2012.05.019.

[8] Li M, Zhang Q, Zhao W, et al. Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial. J Nutr Health Aging. 2025; 29(8): 100598. doi:10.1016/j.jnha.2025.100598.

[9] Goodoory VC, Coelho TCB, Kamperidis N, et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology. 2023; 165(5): 1206-1218. doi:10.1053/j.gastro.2023.07.018.

[10] Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012; 18(30): 4012-4018. doi:10.3748/wjg.v18.i30.4012.

[11] Stevenson C, Blaauw R, Fredericks E, et al. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition. 2014; 30(10): 1151-1157. doi:10.1016/j.nut.2014.02.010.

[12] Sommermeyer H, Chmielowiec K, Bernatek M, et al. Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2024;16(10):1503. doi:10.3390/nu16101503.

[13] Nakamura Y, Suzuki S, Murakami S, et al. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT. Comput Struct Biotechnol J. 2022; 20:5847-5858. doi:10.1016/j.csbj.2022.10.026.

[14] Ramirez-Farias C, Slezak K, Fuller Z, et al. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr. 2009;101(4):541-550. doi:10.1017/S0007114508019880.